VRPX | Virpax Pharmaceuticals, Inc. Annual & Quarterly

Annual Income Statements

(In USD)

Breakdown	2023	2022	2021	2020	2019	2018
Revenue	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses	15.68 Million	21.84 Million	12.02 Million	4.19 Million	3.18 Million	2.62 Million
Selling, General and Administrative Expenses	11.82 Million	11.08 Million	7.18 Million	2.9 Million	2.55 Million	1.48 Million
Research and Development Expenses	5.11 Million	10.76 Million	4.83 Million	1.29 Million	622.74 Thousand	1.14 Million
Other Expenses	-	194.41 Thousand	62.25 Thousand	4000.00	-	-
Cost and Expenses	15.68 Million	21.84 Million	12.02 Million	4.19 Million	3.18 Million	2.62 Million
Operating Income	-15.68 Million	-21.84 Million	-12.02 Million	-4.19 Million	-3.18 Million	-2.62 Million
Interest Expense	-	-	92.82 Thousand	147.93 Thousand	124.64 Thousand	14.97 Thousand
Income Tax Expense	-	-194.41 Thousand	92.82 Thousand	147.93 Thousand	124.64 Thousand	-161.14 Thousand
Earnings before Tax	-15.18 Million	-21.65 Million	-12.05 Million	-4.33 Million	-3.3 Million	-2.64 Million
Net Income	-15.18 Million	-21.45 Million	-12.14 Million	-4.48 Million	-3.43 Million	-2.64 Million
Earnings Per Share Basic	-12.97	-18.32	-10.37	-9.07	-6.58	-0.53
Earnings Per Share Diluted	-12.97	-18.32	-10.37	-9.07	-6.58	-0.53
Weighted Average Shares Outstanding	1.17 Million	1.17 Million	1.17 Million	494.51 Thousand	521.51 Thousand	4.94 Million
Weighted Average Shares Outstanding (Diluted)	1.17 Million	1.17 Million	1.17 Million	494.51 Thousand	521.51 Thousand	4.94 Million
Gross Margin	-	-	-	-	-	-
EBIT Margin	-	-	-	-	-	-
Profit Margin	-	-	-	-	-	-
EBITDA	-2.24 Million	-	-	-4.19 Million	-	-
Earnings Before Tax Margin	-	-	-	-	-	-

Breakdown	2024 Q2	2024 Q1	2023 Q4	2023 FY	2023 Q3	2023 Q2
Revenue	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses	3.45 Million	3.3 Million	4.68 Million	16.93 Million	6.11 Million	3.23 Million
Selling, General and Administrative Expenses	1.5 Million	1.68 Million	3.58 Million	-	4.61 Million	1.94 Million
Research and Development Expenses	1.95 Million	1.61 Million	1.09 Million	-	1.49 Million	1.29 Million
Other Expenses	19.12 Thousand	82.03 Thousand	122.39 Thousand	-	120.64 Thousand	126.72 Thousand
Cost and Expenses	3.45 Million	3.3 Million	4.68 Million	16.93 Million	6.11 Million	3.23 Million
Operating Income	-3.45 Million	-3.3 Million	-4.68 Million	-16.93 Million	-6.11 Million	-3.23 Million
Interest Expense	11 Thousand	-	130.53 Thousand	-	-	-
Income Tax Expense	-3.45 Million	-3.3 Million	-918.10	-12.93 Thousand	-6115.14	-3005.49
Earnings before Tax	-3.45 Million	-3.22 Million	-4.56 Million	-15.18 Million	-5.99 Million	-3.11 Million
Net Income	-3.45 Million	-3.22 Million	-4.56 Million	-15.18 Million	-5.99 Million	-3.11 Million
Earnings Per Share Basic	-1.75	-2.75	-3.89	-	-5.12	-2.66
Earnings Per Share Diluted	-1.75	-2.75	-3.89	-	-5.12	-2.66
Weighted Average Shares Outstanding	1.97 Million	1.17 Million	1.17 Million	1.17 Million	1.17 Million	1.17 Million
Weighted Average Shares Outstanding (Diluted)	1.97 Million	1.17 Million	1.17 Million	1.17 Million	1.17 Million	1.17 Million
Gross Margin	-	-	-	-	-	-
EBIT Margin	-	-	-	-	-	-
Profit Margin	-	-	-	-	-	-
EBITDA	-3.45 Million	-3.3 Million	-4.68 Million	-	-6.11 Million	-3.23 Million
Earnings Before Tax Margin	-	-	-	-	-	-